Study S000482

A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes Mellitus

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT02759107
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 142
Start: 2016-05-11
Primary completion: 2017-06-26
Lead sponsor: Eli Lilly and Company
Conditions: Healthy; Type 2 Diabetes Mellitus (T2DM)
Interventions: DRUG:Tirzepatide; DRUG:Placebo; DRUG:Dulaglutide
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I8F-MC-GPGA

Registered primary outcomes

Number of Participants With One or More Serious Adverse Event(s) (SAEs) [Baseline through Day 43 (Part A) and Day 57 (Part B and C)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014066	LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Coskun T, Molecular metabolism	2018	Randomized trial	PMID 30473097 DOI	cites ClinicalTrials.gov:NCT02759107; registry reference DERIVED:30473097